Expert Reaction

EXPERT REACTION: Methadone helps reduce the death rates of drug addicted offenders

Publicly released:
Australia; International; NSW; QLD

Encouraging convicted offenders to stay in a methadone program may reduce overdose deaths and other rates of death overall, according to Canadian research. The study looked at almost 15,000 people with criminal convictions from 1998 to 2015, who were prescribed methadone, and compared death rates between periods when methadone either was or wasn't given. People were significantly less likely to die during periods when they were taking methadone. Writing in a accompanying comment piece, Australian experts say there are a number of good public health reasons for expanding methadone treatment for opioid dependence. Commenting separately on the study Dr Sarah Larney from UNSW says "access to treatment in correctional settings remains poor in most jurisdictions, even in wealthy countries such as Australia."

News release

From: PLOS

Peer reviewed                             Retrospective Study                                People

Methadone linked to lower death rates among convicted offenders with opioid dependence

Among convicted offenders, receiving methadone is associated with lower rates of death from external and non-external causes, according to new research published this week in PLOS Medicine by Angela Russolillo of Simon Fraser University, Canada, and colleagues.

Deaths caused by opioids are rising acutely throughout North America and individuals with criminal histories experience high rates of opioid dependence and premature mortality. In this new study, researchers analyzed population-level data spanning 1998 to 2015 on 14,530 people with criminal convictions who had been prescribed methadone in British Columbia, Canada. The data included prescriptions, convictions, and deaths; researchers were able to compare overall and cause-specific mortality rates between periods when methadone was and was not dispensed.

The overall all-cause mortality rate was 11.2 per 1000 person-years. Participants were significantly less likely to die from both non-external (adjusted hazard ratio [AHR] 0.27; 95% CI 0.23-0.33) and external (AHR 0.41; 95% CI 0.33- 0.51) causes during periods when they were dispensed methadone, even after controlling for socio-demographic, criminological, and health-related factors. Death due to infectious diseases was 5 times lower (AHR 0.20, 95% CI 0.13-0.30) and deaths due to overdoses were nearly 3 times lower (AHR 0.39, 95% CI 0.30-0.50) during medicated periods. It is unclear whether the results of this study are generalizable to jurisdictions without universal healthcare or to non-offender populations.

“Achieving higher rates of [methadone] adherence may reduce overdose deaths and other causes of mortality among offenders and similarly marginalized populations,” the authors say. “Our findings warrant examination in other study centers in response to the crisis of opioid-involved deaths.”

In an accompanying Perspective, Wayne Hall of the University of Queensland, Australia and Michael Farrell of the University of New South Wales, Australia, write that there are a number of good public health reasons for expanding methadone-assisted treatment for opioid dependence. “If the US government wants to reduce the unconscionable toll that opioid overdose deaths is taking among its citizens, then it needs to adopt the effective public health approaches advocated by expert committees and Commissions,” they say. This should include increasing access to methadone and buprenorphine-assisted treatment and maximizing their uptake by funding educational programs to reduce the stigma of addiction that discourages treatment seeking.”

Expert Reaction

These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.

Dr Sarah Larney is from the National Drug and Alcohol Research Centre, UNSW Sydney. She has undertaken several studies on the use of methadone and buprenorphine to treat opioid dependence in correctional settings.

There is very good evidence that methadone and buprenorphine in correctional settings, with continued treatment in the community, reduces post-release mortality and re-incarceration. However, access to treatment in correctional settings remains poor in most jurisdictions, even in wealthy countries such as Australia.

Last updated:  31 Jul 2018 1:00pm
Contact information
Contact details are only visible to registered journalists.
Declared conflicts of interest None declared.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research PLOS, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).
Editorial / Opinion PLOS, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).
Journal/
conference:
PLOS Medicine
Research:Paper
Organisation/s: The University of Queensland, The University of New South Wales, National Drug and Alcohol Research Centre (NDARC), Simon Fraser University, Canada
Funder: This research was supported by funds provided by the Canadian Institutes of Health Research (AR: GSD-14620; JMS: 2009 s0231), the British Columbia Ministry of Justice (JMS: 2014 s0040), and Health Canada (JMS:2009s0231). There was no specific funding for the comment piece.
Media Contact/s
Contact details are only visible to registered journalists.